Dietrich S, Oles M, Lu J et al. Drug-perturbation-based stratification of blood cancer. J Clin Invest 2018;128:427-445. Krämer I, Stilgenbauer S, Dietrich S …Dreger P. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: 10-year Follow-up of the GCLLSG CLL3X Trial. Blood 2017;130:1477-1480.
Dreger P, Schetelig J, Andersen N et al. Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: Stem cell transplantation or novel agents? A position statement of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Blood 2014;124:3841-3849.
Herth I, Dietrich S, Benner A … Dreger P. The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 2014;25:200-206.
Dreger P, Schnaiter A, Zenz T et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013;121:3284-3288.
Dietrich S, Pircher A, Endris V et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 2016;127:2847-2855.
Dietrich S, Hullein J, Lee SC et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood 2015;126:1005-1008.
Dietrich S, Glimm H, Andrulis M et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038-2040.
Sellner L, Brüggemann M, Schlitt M … Dreger P. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplant. 2017;52:544-551.
